Nattokinasa

Condiciones de salud que Nattokinasa puede ayudar a apoyar.

• Síndrome de Inmunodeficiencia AdquiridaCientífico

  Nattokinase is a potent fibrinolytic enzyme from fermented soybean (natto) with demonstrated antiatherosclerotic, antihypertensive, and endothelial-protective effects in clinical studies. A large clinical study in 1,062 participants at 10,800 FU/day found significant reductions in carotid intima-media thickness and plaque size. It acts through fibrinolysis and antiplatelet mechanisms to maintain arterial patency.

• HipoglucemiaCientífico

  Nattokinase is a fibrinolytic enzyme derived from Bacillus subtilis during soybean fermentation (natto). Multiple human clinical studies confirm it retains fibrinolytic and anticoagulant activity after oral administration, reducing fibrinogen, factor VII, and factor VIII. A 2015 Scientific Reports study demonstrated measurable thrombolytic and anticoagulation effects from a single oral dose. It is undergoing Phase II clinical trials for atherothrombotic prevention.

• HipotensiónCientífico

  Nattokinase, a serine protease from fermented soybeans (natto), has demonstrated significant antihypertensive effects in RCTs and a 2024 meta-analysis. A 2008 randomized controlled trial found 8-week supplementation reduced SBP and DBP in pre-hypertensive and stage 1 hypertensive adults. Mechanisms include fibrinolytic activity, renin inhibition, and improved blood viscosity.

• Válvula IleocecalCientífico

  Multiple RCTs and a 2023 meta-analysis (6 RCTs, n=546) have examined nattokinase's effects on blood lipids. Evidence shows dose-dependent effects on total cholesterol (TC) and LDL-C, particularly at higher doses. A 12-month clinical study in 1,062 participants at 10,800 FU/day found 15.9% reduction in TC and 18.1% reduction in LDL-C. Low-dose supplementation (2,000 FU/day) does not appear to produce significant lipid-lowering effects based on a 3-year RCT.

• ApendicitisCientífico

  Nattokinase exhibits anti-inflammatory properties through inhibition of TLR4 signaling and suppression of pro-inflammatory cytokines such as TNF-α and IL-6. Preclinical studies demonstrate reduction of LPS-induced systemic inflammation and oxidative stress. Human RCTs studying cardiovascular endpoints have incorporated inflammatory markers as secondary outcomes, supporting a plausible anti-inflammatory role, though dedicated clinical trials on chronic inflammation as a primary endpoint remain limited.

• Apetito (excesivo)Científico

  Nattokinase is a fibrinolytic serine protease from fermented soybean (natto) with demonstrated antithrombotic and blood-flow-enhancing effects in humans. A double-blind crossover study in 12 healthy males showed a single oral dose of 2,000 FU significantly elevated fibrinolysis markers and prolonged clotting time. A 2024 systematic review and meta-analysis of 6 RCTs (546 participants) confirmed cardiovascular benefits, and a clinical study of 1,062 participants at 10,800 FU/day showed effective management of atherosclerosis.

• IncontinenciaCientífico

  Nattokinase has been investigated for cognitive benefits through its fibrinolytic, amyloid-degrading, and neuroinflammatory pathways. The ICC-PACS RCT (2025/2026; n=88 completers; 8,000 FU/day for 6 months) in patients with asymptomatic intracranial/carotid stenosis found no significant improvement in global cognition (MoCA) but showed exploratory benefits in visuospatial function. Preclinical data in Alzheimer's models demonstrate NK reduces amyloid-beta plaques, restores BDNF signaling, and reduces neuroinflammatory markers.

• BronquitisCientífico

  Natto consumption has been linked to longevity and healthy aging in Japanese populations for over a millennium, with NK identified as a key bioactive constituent. A 2024 ScienceDirect review critically evaluated 20 years of experimental and clinical evidence supporting NK's role in preventing age-related diseases including cardiovascular disease and Alzheimer's disease. NK's anti-thrombus, fibrinolytic, and anti-inflammatory activities are proposed mechanisms underlying its potential to delay age-related pathology.

• JuanetesCientífico

  Nattokinase is a fibrinolytic serine protease extracted from natto (fermented soybeans) with documented activity against cardiovascular risk factors in multiple human clinical trials. The strongest and most consistent evidence supports a blood pressure-lowering effect, confirmed across randomized controlled trials and a 2023 systematic review/meta-analysis. Evidence for lipid-lowering and anti-atherosclerotic effects exists but is more dose-dependent and less conclusive at lower doses.

• Dolor en el pechoCientífico

  Nattokinase, a fibrinolytic enzyme from fermented soybeans, helps break down fibrin that accumulates in chronic lymphedema tissue, contributing to fibrosis and impaired drainage. A 2021 murine study showed a 30% reduction in fibrotic markers with enzyme supplementation. It is used in combination with serrapeptase and bromelain in systemic enzyme protocols for lymphedema and lymphatic support, with PMC-indexed clinical evidence supporting this application.

• Tos (húmeda)Científico

  Nattokinase is a fibrinolytic enzyme from fermented soybeans with evidence for breaking down fibrin-based scar tissue. It is included in clinical pilot studies on systemic enzyme therapy for fibrosis and scar tissue reduction, showing improvements in tissue quality and symptom burden.

• CortesCientífico

  Nattokinase is a fibrinolytic enzyme from fermented soybeans shown to degrade clotting proteins and reduce venous inflammation. Combined with Pycnogenol in an RCT of 186 subjects at high DVT risk, it significantly reduced clot risk and edema relevant to chronic venous disease including spider veins. It is used as an adjunct in chronic venous disease management.

• DebilidadCientífico

  Human RCT data on nattokinase and triglycerides are mixed and dose-dependent. A 2023 meta-analysis of six RCTs (n=546) found no statistically significant effect of nattokinase on triglyceride levels at low-to-moderate doses. However, a large clinical study (n=1,062) at 10,800 FU/day found a 15.3% reduction in triglycerides over 12 months, and a 90-day RCT in CAD patients found NK combined with red yeast rice reduced triglycerides by 0.39 mmol/L. NK is proposed to activate lipoprotein lipase, enhancing triglyceride catabolism.

• DiabetesCientífico

  Nattokinase is a fibrinolytic enzyme derived from fermented soybeans (natto) with clinical evidence for CVI and varicose vein-associated venous disease. An observational study of 153 CVI/thrombosis patients found complete symptom resolution after 30 days of nattokinase post-initial therapy. When combined with Pycnogenol, it reduced travel-associated clot risk in an RCT of 186 high-risk subjects. Life Extension's clinical protocol includes nattokinase for chronic venous disease management.

• Infección de oído o dolor de oídoTradicional

  Angina (chest pain of cardiac origin) is listed among the traditional indications for nattokinase based on its historical use in Japan for circulatory and cardiac conditions. Natto has been used as a folk remedy for cardiovascular disease for hundreds of years. No RCTs specifically targeting angina as a primary endpoint have been identified; studies in CAD patients (who may have angina) tested lipid and antithrombotic endpoints rather than anginal symptom relief.

• IndigestiónTradicional

  Nattokinase is a serine protease produced by Bacillus subtilis natto during soybean fermentation, traditionally consumed in fermented natto as part of Japanese dietary culture. It is included in some multi-enzyme digestive supplement formulations as a proteolytic component, though its primary well-characterized role is fibrinolytic rather than macronutrient-specific digestion.

• BursitisTradicional

  Nattokinase is listed among traditional uses of natto for circulatory conditions including hemorrhoids, based on the rationale that hemorrhoids involve local venous congestion and fibrin deposition akin to thrombotic conditions. No controlled human clinical trials specifically targeting hemorrhoids have been identified in the peer-reviewed literature. The association rests on documented traditional and folk use of natto in Japan and the theoretical fibrinolytic mechanism.

Sistemas corporales que Nattokinasa puede ayudar a apoyar.

• No hay sistemas corporales disponibles.